ArticleJournal of Alzheimer's disease : JAD2019
Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort.
Article in Journal of Alzheimer's disease : JAD, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Targeting innovative therapeutic approaches to the hallmarks of aging to combat Alzheimer's disease.Neural regeneration research · 2026Article
- Article
- Interactive effects of telomere length and genetic variants on Alzheimer disease risk across multiple ancestral populations.Alzheimer's research & therapy · 2026Article
- Brain Region-Specific Epigenomic Reorganization and Altered Cell States in Alzheimer's Disease.bioRxiv : the preprint server for biology · 2025Article
- Integrative effects of Telomere Length, Epigenetic Age, and Mitochondrial DNA abundance in Alzheimer's Disease.medRxiv : the preprint server for health sciences · 2025Article
- DNA Damage, Telomere and Centromere Dysfunction in Chromothripsis Rearrangements.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Neuroinflammaging: A Tight Line Between Normal Aging and Age-Related Neurodegenerative Disorders.Aging and disease · 2024Review
- Evaluating genomic signatures of aging in brain tissue as it relates to Alzheimer's disease.Scientific reports · 2023Article
- Evaluating genomic signatures of aging in brain tissue as it relates to Alzheimer's disease.Scientific reports · 2023Article
- Integrative analysis of DNA methylation and gene expression identifies genes associated with biological aging in Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Telomere Attrition in Induced Pluripotent Stem Cell-Derived Neurons From ALS/FTD-RelatedFrontiers in cell and developmental biology · 2022Article
- Biomedical applications of metal oxide nanoparticles in aging and age-associated diseases.3 Biotech · 2021Review
- Pathways Connecting Late-Life Depression and Dementia.Frontiers in pharmacology · 2020Review
- Telomere Attrition in Neurodegenerative Disorders.Frontiers in cellular neuroscience · 2020Article
- Telomere length associations with cognition depend on Alzheimer's disease biomarkers.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Exploring the Causal Pathway From Telomere Length to Alzheimer's Disease: An Update Mendelian Randomization Study.Frontiers in psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundAlthough shorter telomeres have been associated with Alzheimer's disease (AD), it is unclear whether longitudinal change in telomere length is associated with AD progression.
objectiveTo investigate the association of telomere length change with AD diagnosis and progression.
methodsIn 653 individuals from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, T/S ratio (telomere versus single copy gene), a proxy of telomere length, was measured for up to five visits per participant (N = 1918 samples post-QC) using quantitative PCR (qPCR). T/S ratio was adjusted for batch effects and DNA storage time. A mixed effects model was used to evaluate association of telomere length with AD diagnostic group and interaction of age and diagnosis. Another mixed effects model was used to compare T/S ratio changes pre- to post-conversion to MCI or AD to telomere change in participants with stable diagnoses.
resultsShorter telomeres were associated with older age (Effect Size (ES) = -0.23) and male sex (ES = -0.26). Neither baseline T/S ratio (ES = -0.036) nor T/S ratio change (ES = 0.046) differed significantly between AD diagnostic groups. MCI/AD converters showed greater, but non-significant, telomere shortening compared to non-converters (ES = -0.186).
conclusionsAlthough AD compared to controls showed small, non-significant effects for baseline T/S ratio and T/S ratio shortening, we did observe a larger, though still non-significant effect for greater telomere shortening in converters compared to non-converters. Although our results do not support telomere shortening as a robust biomarker of AD progression, further investigation in larger samples and for subgroups of participants may be informative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.